Business Group Makes Price Recommendations for Specialty Drugs March 16, 2017By Nicholas HammThe high cost of specialty drugs demands a change in Washington, according to a report. How New Biosimilars Will Impact the Market February 15, 2017By Christine BlankMore biosimilars are coming onto the market , including competitors for Remicade and Neulasta. New diabetes medications help address linked diseasesExperts share updates on new diabetes medications, and provide an overview of what’s coming. Are payers optimistic about biosimilars’ savings? December 07, 2016By Erin BastickAs more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications. Breast cancer biosimilar shows equivalency to brand December 02, 2016By Christine BlankTwo new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency. What executives must know to combat rising drug spendIn today’s healthcare landscape, few things better define the role of a managed healthcare executive than managing the industry’s constant changes. FDA approves biosimilar to Humira September 26, 2016By Christine BlankFDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month. Predictions for biosimilars: How market access will play outEarly planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars. Can costs be contained? September 08, 2016By Lisette HiltonThere’s a lot of blame to go around when it comes to why drug costs are rising in dermatology. We’ll let the research do the finger pointing. Why pharmacists are concerned about the safety of biosimilars August 10, 2016By Christine BlankPharmacists and other healthcare professionals are looking to the FDA for more guidance on biosimilars and interchangeability with their reference products.